Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndrome Post Cytotoxic Therapy: early-phase trial registry
1 of 2 indexed Myelodysplastic Syndrome Post Cytotoxic Therapy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Myelodysplastic Syndrome Post Cytotoxic Therapy: 2 US clinical trials tracked, 1 recruiting.
Myelodysplastic Syndrome Post Cytotoxic Therapy is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is PedAL BCU, running 1 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndrome-post-cytotoxic-therapy
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Myelodysplastic Syndrome Post Cytotoxic Therapy lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndrome Post Cytotoxic Therapy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndrome Post Cytotoxic Therapy is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU
NCT04726241
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
NCT05146739
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndrome Post Cytotoxic Therapy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndrome Post Cytotoxic Therapy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndrome Post Cytotoxic Therapy page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Myelodysplastic Syndrome Post Cytotoxic Therapy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- PedAL BCU sponsors the most Myelodysplastic Syndrome Post Cytotoxic Therapy trials on record, review their full trial history before evaluating a specific study. See PedAL BCU's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndrome Post Cytotoxic Therapy condition card totals 2 registered trials; most-linked intervention Uproleselan; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.